LoginSubscribe Now
International In-house Counsel Journal Logo
International In-house Counsel Journal Logo
  • Home
  • Business Sectors
  • Areas of Law
  • Editorial Board
  • Write a Paper
  • Subscribe
  • Books
  • Reports
  • Back Issues
  • Terms and Conditions
  • Cookie Policy
  • Privacy Policy
  • PLS LogoCopyright & permissions
© 2026 International In-house Counsel Journal Ltd. | ISSN 1754-0607 | Picture Credits: Freepix, Unsplash and by permission of the authors

Library search

Conducting Effective Global Anti–Money Laundering Investigations in a Complex Regulatory Environment
Money LaunderingPharmaceutical
Global anti–money laundering (AML) investigations present complex operational and regulatory challenges driven by cross-border transactions, fragmented data sources, varying legal regimes, data protection and privacy requirements, and cultural barriers to...Read more
Portrait image of Fabiana Lacerca-Allen
Fabiana Lacerca-Allen
Chief Compliance Officer, Cipla, USA
“Crisis-Capable Compliance: The CCO at the Crossroads of AI, Ethics, and Leadership”
CompliancePharmaceutical
The role of the Chief Compliance Officer is undergoing a fundamental transformation in the era of artificial intelligence. No longer confined to oversight and enforcement, the CCO is emerging as...Read more
Portrait image of Fabiana Lacerca-Allen
Fabiana Lacerca-Allen
Chief Compliance Officer, Cipla, USA
Implementing Effective Compliance Programs in Jurisdictions Where the Rule of Law is Weak
CompliancePharmaceutical
Multinational organizations increasingly operate in jurisdictions where the rule of law is weak, inconsistently enforced, or subject to political and economic influence. For pharmaceutical and biotechnology companies, these environments present...Read more
Portrait image of Fabiana Lacerca-Allen
Fabiana Lacerca-Allen
Chief Compliance Officer, Cipla, USA
AI and Inventorship
ITHealthcare
Artificial intelligence (AI) is a cutting-edge technology that has been generating substantial attention worldwide recently, including in the patent community. Balancing the rapid development in AI and adapting the patent...Read more
Portrait image of Anagha Tendulkar
Anagha Tendulkar
In-house Patent Counsel, Cipla, India
Section 112 Requirements for Life Sciences Patents
Intellectual PropertyPharmaceutical
35 U.S.C. §112(a) of the US Patent Act is one of the integral parts of the quid pro quo patent system that balances the benefit of disclosure of the invention...Read more
Portrait image of Anagha Tendulkar
Anagha Tendulkar
In-house Patent Counsel, Cipla, India
Induced Infringement under US Patent Law
Intellectual PropertyPharmaceutical
Induced infringement finds its basis in 35 U.S.C. § 271(b) and holds a person, liable if he actively causes infringement, even if the actor himself is not the direct infringer....Read more
Portrait image of Anagha Tendulkar
Anagha Tendulkar
In-house Patent Counsel, Cipla, India
Written Description Requirement of Patentability
Intellectual PropertyPharmaceutical
One of the requirements for an invention to be patentable is written description, which requires that the invention be described in sufficient detail for one of ordinary skill in the...Read more
Portrait image of Anagha Tendulkar
Anagha Tendulkar
In-house Patent Counsel, Cipla, India
Implementing a Robust Compliance Program in a Remote Environment
ComplianceHealthcare
Implementing an effective Compliance program can be complicated and challenging in the best of times, especially when you operate globally in a rapidly changing environment. These challenges and complexities have...Read more
Portrait image of Fabiana Lacerca-Allen
Fabiana Lacerca-Allen
Chief Compliance Officer, Cipla, USA
Blocking Effect of the Blocking Act?
CompetitionPharmaceutical
The Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch Waxman Act 1984, was enacted in 1984 to balance the privileges offered to brand...Read more
Portrait image of Anagha Tendulkar
Anagha Tendulkar
In-house Patent Counsel, Cipla, India
Managing Compliance Risk in a COVID and Post-COVID World
ManagementPharmaceutical
Managing risk can be complicated in the best of times, and the challenges associated with risk management become even greater when combined with the tremendous disruption caused by a global...Read more
Portrait image of Fabiana Lacerca-Allen
Fabiana Lacerca-Allen
Chief Compliance Officer, Cipla, USA
12